Human mitochondrial proteins and polynucleotides encoding the proteins

ABSTRACT

The invention of the present application provides an isolated and purified human mitochondrial protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which is a novel human protein promoting aggregation and fusion of mitochondria. The present invention also provides a polynucleotide encoding such a mitochondrial protein, antibody against such a mitochondrial protein, and a proteoliposome composed of such a mitochondrial protein and lipid. Mitochondrial proteins are useful for clarifying causes of mitochondrial diseases as well as for developing preventive and therapeutic methods thereof. Furthermore, antibodies and probes derived from genes encoding such proteins are potentially useful materials for diagnosis of condition of mitochondria in particular diseases. Furthermore, proteoliposomes provide measures for specific transfer of foreign genes or drugs targeted toward mitochondria.

TECHNICAL FIELD

[0001] The invention of the present application relates to proteins derived from human mitochondria, polynucleotide encoding such proteins, and antibodies against such proteins. More specifically, the invention of the present application relates to NOVEL HUMAN PROTEINS AND ANTIBODIES which are useful for diagnosis and treatment of a variety of diseases caused by mutation of mitochondrial DNA. The invention also relates to POLYNUCLEOTIDES which are useful as probes for gene diagnosis of the above diseases, gene sources for gene therapy, and gene sources for mass production of the proteins according to the present invention. The invention further relates to LIPOSOMES (LIPOSOME VECTORS) which enable mitochondria-specific transfer of foreign genes or drugs.

BACKGROUND ART

[0002] Mitochondria are organelles each composed of an outer membrane and an inner membrane having a cristae structure, and are distributed throughout cytoplasm in a tubular reticular structure. Mitochondria also have their own genes (mitochondrial DNA) besides nuclear genes.

[0003] Mitochondria have the functions of, for example, producing energy which is necessary for activity of cells, and catalyzing biosynthesis and degradation of crucial biological substances. Mitochondria are also involved in other biological activities such as production of active oxygen and production of apoptosis-inducing signal.

[0004] Mitochondria dynamically change their forms by migration, fusion and disintegration in response to environmental changes in the cell. In particular, under the pathological conditions, such as the case of liver disease, congenital muscular dystrophy, gastric cancer, myeloma, and dilated cardiomyopathy due to abnormality of mitochondrial DNA, mitochondria significantly change their forms and distributions, and express megamitochondria, annular or axle form, or morphological and structural variations having an annular or concentric cristae structure.

[0005] As a mammalian gene in relation to these mitochondria, a gene involved in disintegration of mitochondria is known (J. Cell Biol. 143: 351-358, 1998). On the other hand, as a gene involved in fusion of mitochondria, a gene product Fzo expressed at the time of formation of sperm of drosophila, which promotes mitochondrial fusion (Cell 90: 121-129, 1997), and a gene product Fzo1p which promotes fusion of mitochondria occurring at the time of meiotic division of fission yeast (J. Cell Biol. 143: 359-373, 1998) are known. However, mammalian genes involved in fusion of mitochondria have not been identified.

[0006] Examples of the diseases caused by mutation of mitochondrial DNA include mitochondrial myopathy, cardiomyopathy, type II diabetes, Alzheimer's disease, Parkinson's disease and the like. Such a mutant mitochondrial DNA exists within a cell in the state of heteroplasmy wherein mutant mitochondrial DNA and normal mitochondrial DNA coexist. When the existing ratio of mutant DNA exceeds a predetermined threshold, the cell function deteriorates to lead appearance of disease symptoms. Gene therapeutic methods against these diseases have not been established because, unlike nuclear DNA, mitochondrial DNA exists in mitochondria. As a method which enables gene therapy targeted towards mitochondrial DNA, transfers of foreign mitochondria by means of cybrid method or microinjection (J. Cell Biol. 67: 174-188, 1975, Cell 52: 811-819, 1988) have been reported heretofore. However, these methods entail the drawbacks that large amounts of cytoplasm components other than mitochondria are introduced, and that desired genes and substances cannot be introduced into mitochondria. Therefore, they are far from actual use at present.

[0007] As described above, mitochondria changes their forms in accordance with the pathological condition of particular disease, and a protein promoting aggregation and fusion of mitochondria is thought to be involved in such a morphological change. Therefore, it is expected that isolation of human proteins as described above and detailed analysis of their functions will open new avenues for clarifying causes of mitochondrial diseases in human and developing preventive and therapeutic methods thereof. Moreover, it is expected that antibodies against such proteins and probes derived from genes encoding such proteins will be useful materials for diagnosing conditions of mitochondria in a particular disease.

[0008] Furthermore, protein samples which promote aggregation or fusion of mitochondria are expected to provide new measures for specific transfer of foreign genes and drugs targeted on mitochondria.

DISCLOSURE OF INVENTION

[0009] It is an object of the invention of the present application to provide novel human proteins which promote aggregation or fusion of mitochondria, and polynucleotides encoding such proteins.

[0010] It is also an object of the invention of the present application to provide antibodies against the proteins, and proteoliposomes which contain such protein as an active ingredient.

[0011] In order to achieve the above objects, the present application provides the following inventions (1) to (8).

[0012] (1) An isolated and purified human mitochondrial protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

[0013] (2) A polynucleotide encoding the protein of the invention (1).

[0014] (3) The polynucleotide of the invention (2), which comprises the base sequence for the protein translation region in SEQ ID NO: 1 or SEQ ID NO: 3.

[0015] (4) A polynucleotide with which a polynucleotide having the sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or a part thereof hybridizes under a stringent condition.

[0016] (5) An expression vector, which expresses the polynucleotide of the invention (3) in the in vitro translating system or in a host cell.

[0017] (6) A transformant with the expression vector of the invention (5), which produces the human mitochondrial protein of the invention (1).

[0018] (7) An antibody against the human mitochondrial protein of the invention (1).

[0019] (8) A proteoliposome composed of the human mitochondrial protein of the invention (1) and lipid.

BRIEF DESCRIPTION OF DRAWINGS

[0020]FIG. 1 is a photographic image taken with a confocal laser scanning microscope, showing the condition of mitochondria stained with rhodamine 123 in a HeLa cell into which cDNA of Hfzo genes has been introduced.

[0021]FIG. 2 is a photographic image taken with a confocal laser scanning microscope, showing the mitochondria and localization of Hfzo-GFP fusion proteins in a HeLa cell into which pDs Red1-Mito gene encoding red fluorescent protein having a mitochondrial target signal and Hfzo-GFP fusion genes have been introduced.

BEST MODE FOR CARRYING OUT THE INVENTION

[0022] The protein according to the invention (1) refers to two kinds of isolated and purified human proteins respectively having amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4 (hereinafter, referred to as “Hfzo1 protein” and “Hfzo2 protein”, respectively, or “Hfzo proteins” for both). Each of these proteins coded by nuclear genome is expressed at nucleus, migrates toward mitochondrial membrane to localize there, and thereby functions to promote aggregation and induction of mitochondria. To be more specific, these proteins localized at different mitochondrial membranes are bound with each other, whereby aggregation and fusion among mitochondria are achieved. These proteins are the proteins that are first characterized in mammal. These proteins have coiled-coiled domains, a GTPase domain and transmembrane domains in their primary structure, so that similarity with the primary structure of a device (SNARE, rab, syntaxin or the like) involved in fusion of vesicle is found.

[0023] These Hfzo proteins according to the invention (1) can be obtained, for example, by isolating from mitochondria of human cell, by preparing a peptide by way of chemical synthesis based the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or by producing by recombinant DNA technique using a polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. Among these, the method based on the recombinant DNA technique is preferably used. For example, by preparing an RNA from a vector harboring the polynucleotide (ORF region of cDNA) according to the invention (3) by in vitro transcription, followed by in vitro translation with the use of this RNA as a template, it is possible to achieve in vitro expression of protein. In addition, by recombining the polynucleotide into an appropriate expression vector using known methods, it is possible to express the protein encoded by the polynucleotide on a large scale in prokaryotic cells such as Escherichia coli and Bacillus subtilis, or in eukaryotic cells such as yeast, insect cells and mammalian cells.

[0024] In the case of expressing DNA by in vitro translation and producing the Hfzo protein according to the invention (1), the polynucleotide according to the invention (3) is inserted into a vector having an RNA polymerase promoter to construct a recombinant vector (invention (5)). Then this vector is added to an in vitro translation system such as rabbit reticulocyte lysate or wheat germ extract containing an RNA polymerase corresponding to the promoter, whereby the protein according to the invention (1) is produced in vitro. Examples of the RNA polymerase promoter include T7, T3 and SP6. Examples of vectors containing these RNA polymerase promoters include pCMV-SPORT, pKA1, pCDM8, pT3/T7 18, pT7/3 19 and pBluescript II.

[0025] In the case of expressing DNA in a microorganism such as Escherichia coli to produce the Hfzo protein according to the invention (1), the polynucleotide according to the invention (3) is recombined into an expression vector which is replicable in a microorganism and having an origin, promoter, ribosome binding site, DNA cloning site, terminator and the like, to thereby create an expression vector (invention (5)). Then a host cell is transformed with this expression vector, and the resultant transformant (invention (6)) is cultured. In this manner, a protein encoded by the present polynucleotide can be produced in the microorganism on a large scale. In this case, by expressing DNA in which an initiation codon and a stop codon are added before and after a given translation region, it is possible to obtain a protein fragment including the given region. Alternatively, it may be expressed in the form of a fusion protein with other protein. By cutting this fusion protein with an appropriate protease, it is possible to acquire only a protein portion encoded by the present polynucleotide. Examples of expression vector to be used for Escherichia coli include pUC series, pBluescript II, pET expression system, pGEX expression system, pQE expression system and the like.

[0026] In the case of expressing DNA in an eukaryotic cell to produce the Hfzo protein according to the invention (1), the polynucleotide according to the invention (3) is inserted into an expression vector for eukaryotic cell having a promoter, splicing regions, poly(A) addition site and the like to create a recombinant vector (invention (5)), and then the recombinant vector is introduced into an eukaryotic cell (invention (6)). In this manner the protein according to the invention (1) can be produced in a eukaryotic cell. Examples of the expression vector include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBKCMV, pBK-RSV, EBV vector, pRS, pYES2 and the like. By using pIND/V5-His, pFLAG-CMV-2, pEGFP-N1, pEGFP-C1 and the like as an expression vector, it is possible to express fusion proteins to which various tags such as His tag, FLAG tag, GFP and the like are added. As the eukaryotic cell, mammalian culture cells such as simian kidney cell COS7 and Chinese hamster ovarian cell CHO, Saccharomyces cerevisiae, Schizosaccharomyces pombe, silkworm cell, platanna egg cell are commonly used, however, any eukaryotic cells can be used insofar as they can express the protein according to the invention (1). For introducing the expression vector into the eukaryotic cell, known methods such as electroporation, calcium phosphate method, liposome method and DEAE-dextran method can be used.

[0027] For isolating and purifying an objective protein from the culture following expression the Hfzo protein according to the invention (1) in a prokaryotic or eukaryotic cell, known separating operations are used in combination. Examples of such operations include treatment with denaturant such as urea or with surfactant, ultrasonic treatment, enzyme digestion, salt precipitation or solvent precipitation method, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing, ion-exchange chromatography, hydrophobicity chromatography, affinity chromatography, reverse-phase chromatography and the like.

[0028] The Hfzo protein according to the invention (1) implies peptide fragments (of 5 or more amino acid resides) comprising any partial amino acid sequences of the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4. These peptide fragments can be used as antigens for preparing antibodies. Furthermore, the protein according to the invention (1) implies fusion proteins with other arbitrary proteins. For example, fusion proteins with glutathione-S-transferase (GST) or green fluorescent protein (GFP) can be exemplified. Furthermore, the protein according to the invention (1) possibly undergoes various modifications in a cell after translation. Therefore, proteins resulting from such modifications also fall within the bound of the protein according to the invention (1). Examples of such post-translational modification include leaving of N-terminal methionine, N-terminal acetylation, addition of sugar chain, restrictive lysis by intracellular protease, myristoylation, isoprenylation, phosphorylation, and the like.

[0029] The invention (2) provides a polynucleotide encoding the protein of the invention (1), and implies human nuclear DNA (genomic DNA), mRNA and cDNA thereof (concretely, polynucleotides having base sequences represented by SEQ ID NO: 1 and SEQ ID NO: 3, respectively), and complementary strands thereof.

[0030] The polynucleotide of the invention (3) refers to two kinds of cDNAs comprising a base sequence which constitutes the translation region (open reading frame: ORF) of SEQ ID NO: 1 or SEQ ID NO: 3. Since the protein of the invention (1) is expressed in any cells, by screening human cDNA library constructed from human cells with the use of oligonucleotide probes synthesized on the basis of the base sequence of SEQ ID NO: 1 or SEQ ID NO: 3, it is possible to readily acquire the same clone as the polynucleotide of the invention (3). cDNA is synthesized by using poly(A)+RNA extracted from human cells as a template. The human cells may be those surgically removed from human body or culture cells. cDNA can be synthesized by using known methods (Okayama, H. and Berg, P., (1982) Mol. Cell Biol. 2, 161-170; Gubler, U. and Hoffman, (1983) J. Gene 25, 263-269; Kato, S. et al. (1994) Gene, 150, 243-250). Alternatively, objective cDNA may be synthesized by an RT-PCR method using these poligonucleotides as primers and an mRNA isolated from human cell as a template.

[0031] In general, polymorphism due to individual specificity is often observed in human genes. Therefore, polynucleotides wherein addition or deletion of one or more nucleotide(s) and/or substitution with other nucleotide(s) is made in the base sequence of SEQ ID NO: 1 or SEQ ID NO: 3 also fall within the bound of the polynucleotide according to the invention (3).

[0032] Similarly, proteins wherein addition or deletion of one or more amino acid(s) generated due to these alteration and/or substitution with other amino acid(s) is made also fall within the bound of the protein according to the invention (1) insofar as the have Hfzo protein activity.

[0033] Furthermore, the polynucleotide according to the invention (3) implies DNA fragments (10 bp or more) comprising any partial base sequences of the base sequence of SEQ ID NO: 1 or SEQ ID NO: 3. Also, DNA fragments made up of a sense strand and an antisense strand fall within this bound. These DNA fragments can be used as probes for gene diagnosis.

[0034] The invention (4) provides a polynucleotide to which a polynucleotide comprising a sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3 or a partial continuous sequence thereof will hybridize in a stringent condition, and implies partial regions of nuclear DNA of all mammals including human (DNA fragments), as well as mRNAs and cDNAs thereof. Herein, the term “stringent condition” refers to a condition that allows selective and detectable specific connection between a polynucleotide comprising a base sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or a partial continuous sequence thereof (for example 10 bp or more) and nuclear DNA. The stringent condition is defined by salt concentration, organic solvent (for example, formamide), temperature and other known conditions. That is, stringency is increased by reducing the salt concentration, by increasing the concentration or organic solvent or by elevating the hybridization temperature. For example, the stringent salt concentration is usually about 750 mM or less of NaCl and about 75 mM or less of sodium triphosphate, more preferably about 500 mM or less of NaCl and about 50 mM or less of sodium triphosphate, and most preferably about 250 mM or less of NaCl and about 25 mM or less of sodium triphosphate. The stringent concentration of organic solvent is about 35% or more, and most preferably about 50% or more in the case of formamide. The stringent temperature condition is about 30° C. or more, more preferably about 37° C. or more, and most preferably about 42° C. or more. Examples of other conditions include hybridization time, concentration of washing agent (for example, SDS) and presence/absence of carrier DNA, and combinations of these conditions will provide various stringencies. Also the condition of washing after hybridization will influence on the stringency. This washing condition is also defined by salt concentration and temperature, the less the salt concentration and the higher the temperature, the more the stringency of washing. For example, the stringent salt condition for washing is preferably about 30 mM or less of NaCl and about 3 mM or less of sodium triphosphate, and most preferably about 15 mM or less of NaCl and about 1.5 mM or less of sodium triphosphate. The stringent temperature condition for washing is about 25° C. or more, more preferably about 42° C. or more, and most preferably about 68° C. or more. The mitochondrial DNA fragment according to the invention (4) can be isolated by screening a genome library prepared from human nuclear DNA through hybridization and washing treatment under stringent conditions as described above using the aforementioned polynucleotide as a probe.

[0035] The polynucleotide (genomic DNA fragment) of the present invention (4) includes expression regulating regions (promoter/enhancer, suppresser sequences or the like) with respect to the Hfzo protein coding region. These expression regulating sequences are useful as materials for screening substances which regulate in vivo expression of the Hfzo protein.

[0036] The antibody according to the invention (7) can be obtained from serum of an animal which has been immunized by using the Hfzo protein of the invention (1) as an antigen. As the antigen, peptides that are chemically synthesized based on the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, Hfzo proteins that are expressed in eukaryotic cells or prokaryotic cells can be used. Alternatively, the antibody may be prepared by sampling serum after introducing the aforementioned expression vector for eukaryotic cell into muscle or skin of animal by injection or gene gun (for example, invention disclosed in Japanese Patent Application Publication (JP-A) No. 7-313187). As the animal, mouse, rat, rabbit, goat, chicken and the like can be used. By preparing a hybridoma by fusing a B cell sampled from a spleen of immunized animal with a myeloma, it is possible to produce a monoclonal antibody against the Hfzo protein.

[0037] The invention (8) provides a proteoliposome composed of the Hfzo protein of the invention (1) and lipid, and can be used as a liposome vector which encapsulates foreign genes or drugs so as to achieve mitochondrial specific gene transfer or drug administration. In brief, inventors of the present invention created proteoliposome using a membrane fraction of mouse hepatocyte mitochondria and lipid, encapsulated a fluorescent pigment marker in the proteoliposome, and microinjected the proteoliposome into a mouse fertilized egg, and finally found that the localization of inherent mitochondria coincides with the localization of liposome (Biochem, Biophys, Res. Comm. 278: 183-191, 2000). This suggests that mitochondrial membrane protein constituting the liposome recognizes the same membrane protein of inherent mitochondrial and bind thereto, thereby causing aggregation and fusion of liposome and inherent mitochondria.

[0038] Such a proteoliposome can be constructed by preparing a liposome in a known manner, and mixing the aforementioned Hfzo protein according to the invention (1) with this liposome, followed by freezing, melting and the like operations.

EXAMPLES

[0039] Now the present invention will be explained more concisely and concretely by way of examples, however, it is to be noted that the present invention is not limited to these examples.

Example 1 Cloning of cDNA

[0040] A human EST library was searched on the basis of the base sequence of cDNA of drosophila Fzo gene (Cell 90: 121-129, 1997; GenBank Accession No. U95821), and using highly homologous ESTs as probes, a cDNA library derived from human heart was searched. As a result of this, two positive clones were obtained. 5′ side and 3′ side were synthesized in accordance with RACE (Rapid amplification of cDNA ends) method, to obtain two complete long cDNA sequences (Hfzo1 and Hfzo2).

[0041] Hfzo1 had a total length of 2754 bp (SEQ ID NO: 1), and its ORF encoded Hzo1 protein made up of 741 amino acid residues (SEQ ID NO: 2) and having a molecular mass of about 84 kD. Hfzo2 had a total length of 2754 bp (SEQ ID NO: 3), and its ORF encoded Hzo1 protein made up of 769 amino acid residues (SEQ ID NO: 4) and having a molecular mass of about 87 kD.

[0042] Both of these proteins were identified as a GTPase having transmembrane domains. Specifically, as to the Hfzo1, transmembrane domains were found at the positions 595-607 and 614-628 in SEQ ID NO: 2, while as to the Hfzo2, transmembrane domains were found at the positions 623-635 and 642-656 in SEQ ID NO: 4. The GTPase active site of Hfzo1 was found at the position 76-268 in SEQ ID NO: 2, while the GTPase active site of Hfzo2 was observed at the position 104-296 in SEQ ID NO: 4. In addition, Coiled Coil domains were observed at the positions 360-404 and 689-734 in SEQ ID NO: 2 for Hfzo1, and at the positions 388-432 and 717-762 in SEQ ID NO: 4 for Hfzo2. Furthermore, these genes have alternative splicing at their 5′ terminal exons, and in particular, Hfzo2 protein has a structure predictable as a mitochondrial target signal (position 1-31 in SEQ ID NO: 4).

Example 2 Expression of Hfzo cDNA in HeLa Cell

[0043] Polynucleotides comprising base sequences constituting ORF regions of SEQ ID NO: 1 and SEQ ID NO: 3 were individually inserted into expression vectors (pCMV-SPORT) and coupled thereto, and the resultant recombinant vectors were introduced into HeLa cells, the HeLa cells were stained with rhodamine 123, and the condition of mitochondria was observed.

[0044] The result is shown in FIG. 1. In FIG. 1, the upper stage shows a bright-field image and the lower stage shows a dark-field image. From these images, it was demonstrated that mitochondria aggregate in the vicinity of nuclei in the HeLa cell into which either cDNA of Hfzo1 or cDNA of Hfzo2 has been introduced (middle lane and right lane, respectively), in contrast to the control (left lane) where reticulum mitochondria are observed throughout the cytosol. Also, electromicroscope observation of HeLa cell into which Hfzo2 cDNA has been introduced demonstrated partial induction of mitochondrial inner membrane.

[0045] From these results, it was confirmed that the Hfzo1 and Hfzo2 proteins of the present invention have the function of promoting aggregation and fusion of mitochondria.

[0046] In addition, point mutation analysis with respect to the GTPase active site demonstrated that aggregation of mitochondria depends on GTPase activity.

Example 3 Expression of Hfzo cDNA-GFP Fusion Protein in HeLa Cell

[0047] GFP was coupled to a carboxylic terminal of polynucleotides comprising either of the base sequences constituting ORF regions represented by SEQ ID NO: 1 and SEQ ID NO: 3, and the resultant polynucleotide was inserted and coupled into an expression vector (pCMV-SPORT: Life Technologies), to create a plasmid. The plasmid was co-expressed in a HeLa cell with pDs Red1-Mito plasmid (Clontech) encoding red fluorescent protein having a mitochondrial target signal. Using a confocal laser scanning microscope, mitochondria were observed by red fluorescence and Hfzo1-GFP and Hfzo2-GFP fusion proteins by green fluorescence.

[0048] The results are as shown in FIG. 2. In FIG. 2, the first (in a left-to-right order) lane shows bright-field image, the second lane shows Hfzo-GFP fusion protein observation image (green fluorescence), the third lane shows mitochondria observation image (red fluorescence) and the fourth lane shows a simultaneous observation image of mitochondria and Hfzo-GFP fusion protein. The upper stage shows the HeLa cell into which Hfzo1-GFP cDNA has been introduced, and the middle stage shows the HeLa cell into which Hfzo2-GFP cDNA has been introduced. The lower stage shows an image of mitochondria portion of the HeLa cell into which Hfzo2-GFP cDNA has been introduced, observed at strong magnification. As is apparent from FIG. 2, it was confirmed that both of the Hfzo proteins locate on mitochondrial membrane, and specifically locate at the site where mitochondria aggregate and contact with each other.

Example 4 Preparation of Recombinant Hfzo2 Protein

[0049] Host Escherichia coli BL21 was transformed with an expression vector (pQE and pGEX) into which a polynucleotide comprising the base sequence constituting the ORF region of SEQ ID NO: 3 had been inserted. The bacterial cells were cultured for 5 hours at 37° C. in LB medium, added with IPTG in a final concentration of 0.4 mM, and cultured for another 2.5 hours at 37° C. Bacterial cells were separated by centrifugation, dissolved in a lysis buffer (50 mM Tris HCl (pH7.5), 1 mM EDTA-1% Triton X-100, 0.2% SDS, 0.2 mM PMSF), frozen at −80° C. and melted, and then crushed by ultrasonication. The crushed substances were centrifuged, and Hfzo2 protein was separated and purified from the supernatant.

Example 5 Preparation of Proteoliposome

[0050] 10 mg of soybean phospholipid was dissolved in 1 mL of chloroform, and 50 μl of the solution was evaporated to give a pellet. This pellet was hydrated with 100 μL of 75 mM KCl and 10 mM phosphate buffer (pH 7.0), and freezing-melting cycle was repeated three times. Thereafter, the solution was fractionated through a 0.2 μm filter to prepare a liposome.

[0051] Then this liposome and the purified Hfzo2 protein obtained in Example 4 were mixed in equal amounts, followed by freezing and melting, to prepare a proteoliposome of mono-double layer membrane.

INDUSTRIAL APPLICABILITY

[0052] According to the present invention, novel human proteins which promote aggregation and fusion of mitochondria, polynucleotides encoding such proteins, antibodies against such proteins, and proteoliposomes containing such proteins are provided. Human proteins are useful for clarifying causes of mitochondrial diseases as well as for developing preventive and therapeutic methods thereof. Furthermore, antibodies and probes derived from genes encoding such proteins are potentially useful material for diagnosis of condition of mitochondria in particular diseases. Furthermore, proteoliposome provides measures for specific transfer of foreign genes or drugs targeted toward mitochondria.

1 4 1 2754 DNA Homo sapiens CDS (92)..(2317) 1 ccgcctttaa cttctcggga agatgaggca gtttggcatc tgtggccgag ttgctgttgc 60 cgggtgatag ttggagcgga gacttagcat a atg gca gaa cct gtt tct cca 112 Met Ala Glu Pro Val Ser Pro 1 5 ctg aag cac ttt gtg ctg gct aag aag gcg att act gca atc ttt gac 160 Leu Lys His Phe Val Leu Ala Lys Lys Ala Ile Thr Ala Ile Phe Asp 10 15 20 cag tta ctg gag ttt gtt act gaa gga tca cat ttt gtt gaa gca aca 208 Gln Leu Leu Glu Phe Val Thr Glu Gly Ser His Phe Val Glu Ala Thr 25 30 35 tat aag aat ccg gaa ctt gat cga ata gcc act gaa gat gat ctg gta 256 Tyr Lys Asn Pro Glu Leu Asp Arg Ile Ala Thr Glu Asp Asp Leu Val 40 45 50 55 gaa atg caa gga tat aaa gac aag ctt tcc atc att ggt gag gtg cta 304 Glu Met Gln Gly Tyr Lys Asp Lys Leu Ser Ile Ile Gly Glu Val Leu 60 65 70 tct cgg aga cac atg aag gtg gca ttt ttt ggc agg aca agc agt ggg 352 Ser Arg Arg His Met Lys Val Ala Phe Phe Gly Arg Thr Ser Ser Gly 75 80 85 aag agc tct gtt atc aat gca atg ttg tgg gat aaa gtt ctc cct agt 400 Lys Ser Ser Val Ile Asn Ala Met Leu Trp Asp Lys Val Leu Pro Ser 90 95 100 ggg att ggc cat ata acc aat tgc ttc cta agt gtt gaa gga act gat 448 Gly Ile Gly His Ile Thr Asn Cys Phe Leu Ser Val Glu Gly Thr Asp 105 110 115 gga gat aaa gcc tat ctt atg aca gaa gga tca gat gaa aaa aag agt 496 Gly Asp Lys Ala Tyr Leu Met Thr Glu Gly Ser Asp Glu Lys Lys Ser 120 125 130 135 gtg aag aca gtt aat caa ctg gcc cat gcc ctt cac atg gac aaa gat 544 Val Lys Thr Val Asn Gln Leu Ala His Ala Leu His Met Asp Lys Asp 140 145 150 ttg aaa gct ggc tgt ctt gta cgt gtg ttt tgc cca aaa gca aaa tgt 592 Leu Lys Ala Gly Cys Leu Val Arg Val Phe Cys Pro Lys Ala Lys Cys 155 160 165 gcc ctc ttg aga gat gac ctg gtg tta gta gac agt cca ggc aca gat 640 Ala Leu Leu Arg Asp Asp Leu Val Leu Val Asp Ser Pro Gly Thr Asp 170 175 180 gtc act aca gag ctg gat agc tgg att gat aag ttt tgc cta gat gct 688 Val Thr Thr Glu Leu Asp Ser Trp Ile Asp Lys Phe Cys Leu Asp Ala 185 190 195 gat gtc ttt gtt ttg gtc gca aac tct gaa tca aca cta atg aat acg 736 Asp Val Phe Val Leu Val Ala Asn Ser Glu Ser Thr Leu Met Asn Thr 200 205 210 215 gaa aaa cac ttt ttt cac aag gtg aat gag cgg ctt tcc aag cct aat 784 Glu Lys His Phe Phe His Lys Val Asn Glu Arg Leu Ser Lys Pro Asn 220 225 230 att ttc att ctc aat aat cgt tgg gat gcc tct gca tca gaa cca gaa 832 Ile Phe Ile Leu Asn Asn Arg Trp Asp Ala Ser Ala Ser Glu Pro Glu 235 240 245 tat atg gaa gac gta cgc aga cag cac atg gaa aga tgc ctg cat ttc 880 Tyr Met Glu Asp Val Arg Arg Gln His Met Glu Arg Cys Leu His Phe 250 255 260 ttg gtg gag gag ctc aaa gtt gta aat gct tta gaa gca cag aat cgt 928 Leu Val Glu Glu Leu Lys Val Val Asn Ala Leu Glu Ala Gln Asn Arg 265 270 275 atc ttc ttt gtt tca gca aag gaa gtt ctt agt gct aga aag caa aaa 976 Ile Phe Phe Val Ser Ala Lys Glu Val Leu Ser Ala Arg Lys Gln Lys 280 285 290 295 gca cag ggg atg cca gaa agt ggt gtg gca ctt gct gaa gga ttt cat 1024 Ala Gln Gly Met Pro Glu Ser Gly Val Ala Leu Ala Glu Gly Phe His 300 305 310 gca aga tta cag gaa ttt cag aat ttt gaa caa atc ttt gag gag tgt 1072 Ala Arg Leu Gln Glu Phe Gln Asn Phe Glu Gln Ile Phe Glu Glu Cys 315 320 325 atc tcg cag tca gca gtg aaa aca aag ttc gaa cag cac act atc aga 1120 Ile Ser Gln Ser Ala Val Lys Thr Lys Phe Glu Gln His Thr Ile Arg 330 335 340 gct aaa cag ata cta gct act gtg aaa aac ata atg gat tca gta aac 1168 Ala Lys Gln Ile Leu Ala Thr Val Lys Asn Ile Met Asp Ser Val Asn 345 350 355 ctg gca gct gaa gat aaa agg cat tat tca gtg gaa gag agg gaa gac 1216 Leu Ala Ala Glu Asp Lys Arg His Tyr Ser Val Glu Glu Arg Glu Asp 360 365 370 375 caa att gat aga ctg gac ttt att cga aac cag atg aac ctt tta aca 1264 Gln Ile Asp Arg Leu Asp Phe Ile Arg Asn Gln Met Asn Leu Leu Thr 380 385 390 ctg gat gtt aag aaa aaa atc aag gag gtt acc gag gag gtg cca aac 1312 Leu Asp Val Lys Lys Lys Ile Lys Glu Val Thr Glu Glu Val Pro Asn 395 400 405 aaa gtt tca tgt gca atg aca gat gaa att tgt cga ctg tct gtt ttg 1360 Lys Val Ser Cys Ala Met Thr Asp Glu Ile Cys Arg Leu Ser Val Leu 410 415 420 gtt gat gaa ttt tgt tca gag ttt cat cct aat cca gat gta tta aaa 1408 Val Asp Glu Phe Cys Ser Glu Phe His Pro Asn Pro Asp Val Leu Lys 425 430 435 ata tat aaa agt gaa tta aat aag cac ata gag gat ggt atg gga aga 1456 Ile Tyr Lys Ser Glu Leu Asn Lys His Ile Glu Asp Gly Met Gly Arg 440 445 450 455 aat ttg gct gat cga tgc acc gat gaa gta aac gcc tta gtg ctt cag 1504 Asn Leu Ala Asp Arg Cys Thr Asp Glu Val Asn Ala Leu Val Leu Gln 460 465 470 acc cag caa gaa att att gaa aat ttg aag cca tta ctt cca gct ggt 1552 Thr Gln Gln Glu Ile Ile Glu Asn Leu Lys Pro Leu Leu Pro Ala Gly 475 480 485 ata cag gat aaa cta cat aca ctg atc cct tgc aag aaa ttt gat ctc 1600 Ile Gln Asp Lys Leu His Thr Leu Ile Pro Cys Lys Lys Phe Asp Leu 490 495 500 agt tat aat cta aat tac cac aag tta tgt tca gat ttt caa gag gat 1648 Ser Tyr Asn Leu Asn Tyr His Lys Leu Cys Ser Asp Phe Gln Glu Asp 505 510 515 att gta ttt cgt ttt tcc ctg ggc tgg tct tcc ctt gta cat cga ttt 1696 Ile Val Phe Arg Phe Ser Leu Gly Trp Ser Ser Leu Val His Arg Phe 520 525 530 535 ttg ggc cct aga aat gct caa agg gtg ctc cta gga tta tca gag cct 1744 Leu Gly Pro Arg Asn Ala Gln Arg Val Leu Leu Gly Leu Ser Glu Pro 540 545 550 atc ttt cag ctc cct aga tct tta gct tct act ccc act gct cct acc 1792 Ile Phe Gln Leu Pro Arg Ser Leu Ala Ser Thr Pro Thr Ala Pro Thr 555 560 565 act cca gca acg cca gat aat gca tca cag gaa gaa ctc atg att aca 1840 Thr Pro Ala Thr Pro Asp Asn Ala Ser Gln Glu Glu Leu Met Ile Thr 570 575 580 tta gta aca gga ttg gcg tcc gtt aca tct aga act tct atg ggc atc 1888 Leu Val Thr Gly Leu Ala Ser Val Thr Ser Arg Thr Ser Met Gly Ile 585 590 595 att att gtt gga gga gtg att tgg aaa act ata ggc tgg aaa ctc cta 1936 Ile Ile Val Gly Gly Val Ile Trp Lys Thr Ile Gly Trp Lys Leu Leu 600 605 610 615 tct gtt tca tta act atg tat gga gct ttg tat ctt tat gaa aga ctg 1984 Ser Val Ser Leu Thr Met Tyr Gly Ala Leu Tyr Leu Tyr Glu Arg Leu 620 625 630 agc tgg acc acc cat gcc aag gag cga gcc ttt aaa cag cag ttt gta 2032 Ser Trp Thr Thr His Ala Lys Glu Arg Ala Phe Lys Gln Gln Phe Val 635 640 645 aac tat gca act gaa aaa ctg agg atg att gtt agc tcc acg agt gca 2080 Asn Tyr Ala Thr Glu Lys Leu Arg Met Ile Val Ser Ser Thr Ser Ala 650 655 660 aac tgc agt cac caa gta aaa caa caa ata gct acc act ttt gct cgc 2128 Asn Cys Ser His Gln Val Lys Gln Gln Ile Ala Thr Thr Phe Ala Arg 665 670 675 ctg tgc caa caa gtt gat att acc cac aaa cag ctg gaa gaa gaa att 2176 Leu Cys Gln Gln Val Asp Ile Thr His Lys Gln Leu Glu Glu Glu Ile 680 685 690 695 gct aga tta ccc aaa gaa ata gat cag ttg gag aaa atc caa aac aat 2224 Ala Arg Leu Pro Lys Glu Ile Asp Gln Leu Glu Lys Ile Gln Asn Asn 700 705 710 tca aag ctc tta aga aat aaa gct gtt caa ctt gaa aat gag ctg gag 2272 Ser Lys Leu Leu Arg Asn Lys Ala Val Gln Leu Glu Asn Glu Leu Glu 715 720 725 aat ttt act aag cag ttt cta cct tca agc aat gaa gaa tcc taa 2317 Asn Phe Thr Lys Gln Phe Leu Pro Ser Ser Asn Glu Glu Ser 730 735 740 caatagagat tgctttggtg accatgatag gaggaaacga aacttgtaag attggaacag 2377 ttgttatttt tatgaaatta ctttaaatat gaattgtact atctgtacct aaatagcaaa 2437 gccctgtgta gattctggta atgatctgtc tcagggtatg tgtatttttg aagagtgtta 2497 tgtccttagt tttaattttg agtaaagaaa aggctaaaat catgaattag ttacaagcaa 2557 cagtaccaac ttatgtgacc cctgaggggt ggggctgtga gctcttaatt tgtttttgat 2617 tctgaaaaac tctgcttcct ggcatccagg agttagagat tgagcctttc atcttctttc 2677 tcaacactag tttttgatgc tttctttcat gggaatagtc acttttttat ttagtaaatc 2737 gcattgctgg aaccacc 2754 2 741 PRT Homo sapiens 2 Met Ala Glu Pro Val Ser Pro Leu Lys His Phe Val Leu Ala Lys Lys 1 5 10 15 Ala Ile Thr Ala Ile Phe Asp Gln Leu Leu Glu Phe Val Thr Glu Gly 20 25 30 Ser His Phe Val Glu Ala Thr Tyr Lys Asn Pro Glu Leu Asp Arg Ile 35 40 45 Ala Thr Glu Asp Asp Leu Val Glu Met Gln Gly Tyr Lys Asp Lys Leu 50 55 60 Ser Ile Ile Gly Glu Val Leu Ser Arg Arg His Met Lys Val Ala Phe 65 70 75 80 Phe Gly Arg Thr Ser Ser Gly Lys Ser Ser Val Ile Asn Ala Met Leu 85 90 95 Trp Asp Lys Val Leu Pro Ser Gly Ile Gly His Ile Thr Asn Cys Phe 100 105 110 Leu Ser Val Glu Gly Thr Asp Gly Asp Lys Ala Tyr Leu Met Thr Glu 115 120 125 Gly Ser Asp Glu Lys Lys Ser Val Lys Thr Val Asn Gln Leu Ala His 130 135 140 Ala Leu His Met Asp Lys Asp Leu Lys Ala Gly Cys Leu Val Arg Val 145 150 155 160 Phe Cys Pro Lys Ala Lys Cys Ala Leu Leu Arg Asp Asp Leu Val Leu 165 170 175 Val Asp Ser Pro Gly Thr Asp Val Thr Thr Glu Leu Asp Ser Trp Ile 180 185 190 Asp Lys Phe Cys Leu Asp Ala Asp Val Phe Val Leu Val Ala Asn Ser 195 200 205 Glu Ser Thr Leu Met Asn Thr Glu Lys His Phe Phe His Lys Val Asn 210 215 220 Glu Arg Leu Ser Lys Pro Asn Ile Phe Ile Leu Asn Asn Arg Trp Asp 225 230 235 240 Ala Ser Ala Ser Glu Pro Glu Tyr Met Glu Asp Val Arg Arg Gln His 245 250 255 Met Glu Arg Cys Leu His Phe Leu Val Glu Glu Leu Lys Val Val Asn 260 265 270 Ala Leu Glu Ala Gln Asn Arg Ile Phe Phe Val Ser Ala Lys Glu Val 275 280 285 Leu Ser Ala Arg Lys Gln Lys Ala Gln Gly Met Pro Glu Ser Gly Val 290 295 300 Ala Leu Ala Glu Gly Phe His Ala Arg Leu Gln Glu Phe Gln Asn Phe 305 310 315 320 Glu Gln Ile Phe Glu Glu Cys Ile Ser Gln Ser Ala Val Lys Thr Lys 325 330 335 Phe Glu Gln His Thr Ile Arg Ala Lys Gln Ile Leu Ala Thr Val Lys 340 345 350 Asn Ile Met Asp Ser Val Asn Leu Ala Ala Glu Asp Lys Arg His Tyr 355 360 365 Ser Val Glu Glu Arg Glu Asp Gln Ile Asp Arg Leu Asp Phe Ile Arg 370 375 380 Asn Gln Met Asn Leu Leu Thr Leu Asp Val Lys Lys Lys Ile Lys Glu 385 390 395 400 Val Thr Glu Glu Val Pro Asn Lys Val Ser Cys Ala Met Thr Asp Glu 405 410 415 Ile Cys Arg Leu Ser Val Leu Val Asp Glu Phe Cys Ser Glu Phe His 420 425 430 Pro Asn Pro Asp Val Leu Lys Ile Tyr Lys Ser Glu Leu Asn Lys His 435 440 445 Ile Glu Asp Gly Met Gly Arg Asn Leu Ala Asp Arg Cys Thr Asp Glu 450 455 460 Val Asn Ala Leu Val Leu Gln Thr Gln Gln Glu Ile Ile Glu Asn Leu 465 470 475 480 Lys Pro Leu Leu Pro Ala Gly Ile Gln Asp Lys Leu His Thr Leu Ile 485 490 495 Pro Cys Lys Lys Phe Asp Leu Ser Tyr Asn Leu Asn Tyr His Lys Leu 500 505 510 Cys Ser Asp Phe Gln Glu Asp Ile Val Phe Arg Phe Ser Leu Gly Trp 515 520 525 Ser Ser Leu Val His Arg Phe Leu Gly Pro Arg Asn Ala Gln Arg Val 530 535 540 Leu Leu Gly Leu Ser Glu Pro Ile Phe Gln Leu Pro Arg Ser Leu Ala 545 550 555 560 Ser Thr Pro Thr Ala Pro Thr Thr Pro Ala Thr Pro Asp Asn Ala Ser 565 570 575 Gln Glu Glu Leu Met Ile Thr Leu Val Thr Gly Leu Ala Ser Val Thr 580 585 590 Ser Arg Thr Ser Met Gly Ile Ile Ile Val Gly Gly Val Ile Trp Lys 595 600 605 Thr Ile Gly Trp Lys Leu Leu Ser Val Ser Leu Thr Met Tyr Gly Ala 610 615 620 Leu Tyr Leu Tyr Glu Arg Leu Ser Trp Thr Thr His Ala Lys Glu Arg 625 630 635 640 Ala Phe Lys Gln Gln Phe Val Asn Tyr Ala Thr Glu Lys Leu Arg Met 645 650 655 Ile Val Ser Ser Thr Ser Ala Asn Cys Ser His Gln Val Lys Gln Gln 660 665 670 Ile Ala Thr Thr Phe Ala Arg Leu Cys Gln Gln Val Asp Ile Thr His 675 680 685 Lys Gln Leu Glu Glu Glu Ile Ala Arg Leu Pro Lys Glu Ile Asp Gln 690 695 700 Leu Glu Lys Ile Gln Asn Asn Ser Lys Leu Leu Arg Asn Lys Ala Val 705 710 715 720 Gln Leu Glu Asn Glu Leu Glu Asn Phe Thr Lys Gln Phe Leu Pro Ser 725 730 735 Ser Asn Glu Glu Ser 740 3 2754 DNA Homo sapiens CDS (8)..(2317) 3 ttgatga atg tca ctg gtg tgt cat cag ttt gca tgt cta tca tcc act 49 Met Ser Leu Val Cys His Gln Phe Ala Cys Leu Ser Ser Thr 1 5 10 tta gtt ggt gct ttt cta act tta tct ccc tct agt agc ata atg gca 97 Leu Val Gly Ala Phe Leu Thr Leu Ser Pro Ser Ser Ser Ile Met Ala 15 20 25 30 gaa cct gtt tct cca ctg aag cac ttt gtg ctg gct aag aag gcg att 145 Glu Pro Val Ser Pro Leu Lys His Phe Val Leu Ala Lys Lys Ala Ile 35 40 45 act gca atc ttt gac cag tta ctg gag ttt gtt act gaa gga tca cat 193 Thr Ala Ile Phe Asp Gln Leu Leu Glu Phe Val Thr Glu Gly Ser His 50 55 60 ttt gtt gaa gca aca tat aag aat ccg gaa ctt gat cga ata gcc act 241 Phe Val Glu Ala Thr Tyr Lys Asn Pro Glu Leu Asp Arg Ile Ala Thr 65 70 75 gaa gat gat ctg gta gaa atg caa gga tat aaa gac aag ctt tcc atc 289 Glu Asp Asp Leu Val Glu Met Gln Gly Tyr Lys Asp Lys Leu Ser Ile 80 85 90 att ggt gag gtg cta tct cgg aga cac atg aag gtg gca ttt ttt ggc 337 Ile Gly Glu Val Leu Ser Arg Arg His Met Lys Val Ala Phe Phe Gly 95 100 105 110 agg aca agc agt ggg aag agc tct gtt atc aat gca atg ttg tgg gat 385 Arg Thr Ser Ser Gly Lys Ser Ser Val Ile Asn Ala Met Leu Trp Asp 115 120 125 aaa gtt ctc cct agt ggg att ggc cat ata acc aat tgc ttc cta agt 433 Lys Val Leu Pro Ser Gly Ile Gly His Ile Thr Asn Cys Phe Leu Ser 130 135 140 gtt gaa gga act gat gga gat aaa gcc tat ctt atg aca gaa gga tca 481 Val Glu Gly Thr Asp Gly Asp Lys Ala Tyr Leu Met Thr Glu Gly Ser 145 150 155 gat gaa aaa aag agt gtg aag aca gtt aat caa ctg gcc cat gcc ctt 529 Asp Glu Lys Lys Ser Val Lys Thr Val Asn Gln Leu Ala His Ala Leu 160 165 170 cac atg gac aaa gat ttg aaa gct ggc tgt ctt gta cgt gtg ttt tgc 577 His Met Asp Lys Asp Leu Lys Ala Gly Cys Leu Val Arg Val Phe Cys 175 180 185 190 cca aaa gca aaa tgt gcc ctc ttg aga gat gac ctg gtg tta gta gac 625 Pro Lys Ala Lys Cys Ala Leu Leu Arg Asp Asp Leu Val Leu Val Asp 195 200 205 agt cca ggc aca gat gtc act aca gag ctg gat agc tgg att gat aag 673 Ser Pro Gly Thr Asp Val Thr Thr Glu Leu Asp Ser Trp Ile Asp Lys 210 215 220 ttt tgc cta gat gct gat gtc ttt gtt ttg gtc gca aac tct gaa tca 721 Phe Cys Leu Asp Ala Asp Val Phe Val Leu Val Ala Asn Ser Glu Ser 225 230 235 aca cta atg aat acg gaa aaa cac ttt ttt cac aag gtg aat gag cgg 769 Thr Leu Met Asn Thr Glu Lys His Phe Phe His Lys Val Asn Glu Arg 240 245 250 ctt tcc aag cct aat att ttc att ctc aat aat cgt tgg gat gcc tct 817 Leu Ser Lys Pro Asn Ile Phe Ile Leu Asn Asn Arg Trp Asp Ala Ser 255 260 265 270 gca tca gaa cca gaa tat atg gaa gac gta cgc aga cag cac atg gaa 865 Ala Ser Glu Pro Glu Tyr Met Glu Asp Val Arg Arg Gln His Met Glu 275 280 285 aga tgc ctg cat ttc ttg gtg gag gag ctc aaa gtt gta aat gct tta 913 Arg Cys Leu His Phe Leu Val Glu Glu Leu Lys Val Val Asn Ala Leu 290 295 300 gaa gca cag aat cgt atc ttc ttt gtt tca gca aag gaa gtt ctt agt 961 Glu Ala Gln Asn Arg Ile Phe Phe Val Ser Ala Lys Glu Val Leu Ser 305 310 315 gct aga aag caa aaa gca cag ggg atg cca gaa agt ggt gtg gca ctt 1009 Ala Arg Lys Gln Lys Ala Gln Gly Met Pro Glu Ser Gly Val Ala Leu 320 325 330 gct gaa gga ttt cat gca aga tta cag gaa ttt cag aat ttt gaa caa 1057 Ala Glu Gly Phe His Ala Arg Leu Gln Glu Phe Gln Asn Phe Glu Gln 335 340 345 350 atc ttt gag gag tgt atc tcg cag tca gca gtg aaa aca aag ttc gaa 1105 Ile Phe Glu Glu Cys Ile Ser Gln Ser Ala Val Lys Thr Lys Phe Glu 355 360 365 cag cac act atc aga gct aaa cag ata cta gct act gtg aaa aac ata 1153 Gln His Thr Ile Arg Ala Lys Gln Ile Leu Ala Thr Val Lys Asn Ile 370 375 380 atg gat tca gta aac ctg gca gct gaa gat aaa agg cat tat tca gtg 1201 Met Asp Ser Val Asn Leu Ala Ala Glu Asp Lys Arg His Tyr Ser Val 385 390 395 gaa gag agg gaa gac caa att gat aga ctg gac ttt att cga aac cag 1249 Glu Glu Arg Glu Asp Gln Ile Asp Arg Leu Asp Phe Ile Arg Asn Gln 400 405 410 atg aac ctt tta aca ctg gat gtt aag aaa aaa atc aag gag gtt acc 1297 Met Asn Leu Leu Thr Leu Asp Val Lys Lys Lys Ile Lys Glu Val Thr 415 420 425 430 gag gag gtg cca aac aaa gtt tca tgt gca atg aca gat gaa att tgt 1345 Glu Glu Val Pro Asn Lys Val Ser Cys Ala Met Thr Asp Glu Ile Cys 435 440 445 cga ctg tct gtt ttg gtt gat gaa ttt tgt tca gag ttt cat cct aat 1393 Arg Leu Ser Val Leu Val Asp Glu Phe Cys Ser Glu Phe His Pro Asn 450 455 460 cca gat gta tta aaa ata tat aaa agt gaa tta aat aag cac ata gag 1441 Pro Asp Val Leu Lys Ile Tyr Lys Ser Glu Leu Asn Lys His Ile Glu 465 470 475 gat ggt atg gga aga aat ttg gct gat cga tgc acc gat gaa gta aac 1489 Asp Gly Met Gly Arg Asn Leu Ala Asp Arg Cys Thr Asp Glu Val Asn 480 485 490 gcc tta gtg ctt cag acc cag caa gaa att att gaa aat ttg aag cca 1537 Ala Leu Val Leu Gln Thr Gln Gln Glu Ile Ile Glu Asn Leu Lys Pro 495 500 505 510 tta ctt cca gct ggt ata cag gat aaa cta cat aca ctg atc cct tgc 1585 Leu Leu Pro Ala Gly Ile Gln Asp Lys Leu His Thr Leu Ile Pro Cys 515 520 525 aag aaa ttt gat ctc agt tat aat cta aat tac cac aag tta tgt tca 1633 Lys Lys Phe Asp Leu Ser Tyr Asn Leu Asn Tyr His Lys Leu Cys Ser 530 535 540 gat ttt caa gag gat att gta ttt cgt ttt tcc ctg ggc tgg tct tcc 1681 Asp Phe Gln Glu Asp Ile Val Phe Arg Phe Ser Leu Gly Trp Ser Ser 545 550 555 ctt gta cat cga ttt ttg ggc cct aga aat gct caa agg gtg ctc cta 1729 Leu Val His Arg Phe Leu Gly Pro Arg Asn Ala Gln Arg Val Leu Leu 560 565 570 gga tta tca gag cct atc ttt cag ctc cct aga tct tta gct tct act 1777 Gly Leu Ser Glu Pro Ile Phe Gln Leu Pro Arg Ser Leu Ala Ser Thr 575 580 585 590 ccc act gct cct acc act cca gca acg cca gat aat gca tca cag gaa 1825 Pro Thr Ala Pro Thr Thr Pro Ala Thr Pro Asp Asn Ala Ser Gln Glu 595 600 605 gaa ctc atg att aca tta gta aca gga ttg gcg tcc gtt aca tct aga 1873 Glu Leu Met Ile Thr Leu Val Thr Gly Leu Ala Ser Val Thr Ser Arg 610 615 620 act tct atg ggc atc att att gtt gga gga gtg att tgg aaa act ata 1921 Thr Ser Met Gly Ile Ile Ile Val Gly Gly Val Ile Trp Lys Thr Ile 625 630 635 ggc tgg aaa ctc cta tct gtt tca tta act atg tat gga gct ttg tat 1969 Gly Trp Lys Leu Leu Ser Val Ser Leu Thr Met Tyr Gly Ala Leu Tyr 640 645 650 ctt tat gaa aga ctg agc tgg acc acc cat gcc aag gag cga gcc ttt 2017 Leu Tyr Glu Arg Leu Ser Trp Thr Thr His Ala Lys Glu Arg Ala Phe 655 660 665 670 aaa cag cag ttt gta aac tat gca act gaa aaa ctg agg atg att gtt 2065 Lys Gln Gln Phe Val Asn Tyr Ala Thr Glu Lys Leu Arg Met Ile Val 675 680 685 agc tcc acg agt gca aac tgc agt cac caa gta aaa caa caa ata gct 2113 Ser Ser Thr Ser Ala Asn Cys Ser His Gln Val Lys Gln Gln Ile Ala 690 695 700 acc act ttt gct cgc ctg tgc caa caa gtt gat att acc cac aaa cag 2161 Thr Thr Phe Ala Arg Leu Cys Gln Gln Val Asp Ile Thr His Lys Gln 705 710 715 ctg gaa gaa gaa att gct aga tta ccc aaa gaa ata gat cag ttg gag 2209 Leu Glu Glu Glu Ile Ala Arg Leu Pro Lys Glu Ile Asp Gln Leu Glu 720 725 730 aaa atc caa aac aat tca aag ctc tta aga aat aaa gct gtt caa ctt 2257 Lys Ile Gln Asn Asn Ser Lys Leu Leu Arg Asn Lys Ala Val Gln Leu 735 740 745 750 gaa aat gag ctg gag aat ttt act aag cag ttt cta cct tca agc aat 2305 Glu Asn Glu Leu Glu Asn Phe Thr Lys Gln Phe Leu Pro Ser Ser Asn 755 760 765 gaa gaa tcc taa caatagagat tgctttggtg accatgatag gaggaaacga 2357 Glu Glu Ser 770 aacttgtaag attggaacag ttgttatttt tatgaaatta ctttaaatat gaattgtact 2417 atctgtacct aaatagcaaa gccctgtgta gattctggta atgatctgtc tcagggtatg 2477 tgtatttttg aagagtgtta tgtccttagt tttaattttg agtaaagaaa aggctaaaat 2537 catgaattag ttacaagcaa cagtaccaac ttatgtgacc cctgaggggt ggggctgtga 2597 gctcttaatt tgtttttgat tctgaaaaac tctgcttcct ggcatccagg agttagagat 2657 tgagcctttc atcttctttc tcaacactag tttttgatgc tttctttcat gggaatagtc 2717 acttttttat ttagtaaatc gcattgctgg aaccacc 2754 4 769 PRT Homo sapiens 4 Met Ser Leu Val Cys His Gln Phe Ala Cys Leu Ser Ser Thr Leu Val 1 5 10 15 Gly Ala Phe Leu Thr Leu Ser Pro Ser Ser Ser Ile Met Ala Glu Pro 20 25 30 Val Ser Pro Leu Lys His Phe Val Leu Ala Lys Lys Ala Ile Thr Ala 35 40 45 Ile Phe Asp Gln Leu Leu Glu Phe Val Thr Glu Gly Ser His Phe Val 50 55 60 Glu Ala Thr Tyr Lys Asn Pro Glu Leu Asp Arg Ile Ala Thr Glu Asp 65 70 75 80 Asp Leu Val Glu Met Gln Gly Tyr Lys Asp Lys Leu Ser Ile Ile Gly 85 90 95 Glu Val Leu Ser Arg Arg His Met Lys Val Ala Phe Phe Gly Arg Thr 100 105 110 Ser Ser Gly Lys Ser Ser Val Ile Asn Ala Met Leu Trp Asp Lys Val 115 120 125 Leu Pro Ser Gly Ile Gly His Ile Thr Asn Cys Phe Leu Ser Val Glu 130 135 140 Gly Thr Asp Gly Asp Lys Ala Tyr Leu Met Thr Glu Gly Ser Asp Glu 145 150 155 160 Lys Lys Ser Val Lys Thr Val Asn Gln Leu Ala His Ala Leu His Met 165 170 175 Asp Lys Asp Leu Lys Ala Gly Cys Leu Val Arg Val Phe Cys Pro Lys 180 185 190 Ala Lys Cys Ala Leu Leu Arg Asp Asp Leu Val Leu Val Asp Ser Pro 195 200 205 Gly Thr Asp Val Thr Thr Glu Leu Asp Ser Trp Ile Asp Lys Phe Cys 210 215 220 Leu Asp Ala Asp Val Phe Val Leu Val Ala Asn Ser Glu Ser Thr Leu 225 230 235 240 Met Asn Thr Glu Lys His Phe Phe His Lys Val Asn Glu Arg Leu Ser 245 250 255 Lys Pro Asn Ile Phe Ile Leu Asn Asn Arg Trp Asp Ala Ser Ala Ser 260 265 270 Glu Pro Glu Tyr Met Glu Asp Val Arg Arg Gln His Met Glu Arg Cys 275 280 285 Leu His Phe Leu Val Glu Glu Leu Lys Val Val Asn Ala Leu Glu Ala 290 295 300 Gln Asn Arg Ile Phe Phe Val Ser Ala Lys Glu Val Leu Ser Ala Arg 305 310 315 320 Lys Gln Lys Ala Gln Gly Met Pro Glu Ser Gly Val Ala Leu Ala Glu 325 330 335 Gly Phe His Ala Arg Leu Gln Glu Phe Gln Asn Phe Glu Gln Ile Phe 340 345 350 Glu Glu Cys Ile Ser Gln Ser Ala Val Lys Thr Lys Phe Glu Gln His 355 360 365 Thr Ile Arg Ala Lys Gln Ile Leu Ala Thr Val Lys Asn Ile Met Asp 370 375 380 Ser Val Asn Leu Ala Ala Glu Asp Lys Arg His Tyr Ser Val Glu Glu 385 390 395 400 Arg Glu Asp Gln Ile Asp Arg Leu Asp Phe Ile Arg Asn Gln Met Asn 405 410 415 Leu Leu Thr Leu Asp Val Lys Lys Lys Ile Lys Glu Val Thr Glu Glu 420 425 430 Val Pro Asn Lys Val Ser Cys Ala Met Thr Asp Glu Ile Cys Arg Leu 435 440 445 Ser Val Leu Val Asp Glu Phe Cys Ser Glu Phe His Pro Asn Pro Asp 450 455 460 Val Leu Lys Ile Tyr Lys Ser Glu Leu Asn Lys His Ile Glu Asp Gly 465 470 475 480 Met Gly Arg Asn Leu Ala Asp Arg Cys Thr Asp Glu Val Asn Ala Leu 485 490 495 Val Leu Gln Thr Gln Gln Glu Ile Ile Glu Asn Leu Lys Pro Leu Leu 500 505 510 Pro Ala Gly Ile Gln Asp Lys Leu His Thr Leu Ile Pro Cys Lys Lys 515 520 525 Phe Asp Leu Ser Tyr Asn Leu Asn Tyr His Lys Leu Cys Ser Asp Phe 530 535 540 Gln Glu Asp Ile Val Phe Arg Phe Ser Leu Gly Trp Ser Ser Leu Val 545 550 555 560 His Arg Phe Leu Gly Pro Arg Asn Ala Gln Arg Val Leu Leu Gly Leu 565 570 575 Ser Glu Pro Ile Phe Gln Leu Pro Arg Ser Leu Ala Ser Thr Pro Thr 580 585 590 Ala Pro Thr Thr Pro Ala Thr Pro Asp Asn Ala Ser Gln Glu Glu Leu 595 600 605 Met Ile Thr Leu Val Thr Gly Leu Ala Ser Val Thr Ser Arg Thr Ser 610 615 620 Met Gly Ile Ile Ile Val Gly Gly Val Ile Trp Lys Thr Ile Gly Trp 625 630 635 640 Lys Leu Leu Ser Val Ser Leu Thr Met Tyr Gly Ala Leu Tyr Leu Tyr 645 650 655 Glu Arg Leu Ser Trp Thr Thr His Ala Lys Glu Arg Ala Phe Lys Gln 660 665 670 Gln Phe Val Asn Tyr Ala Thr Glu Lys Leu Arg Met Ile Val Ser Ser 675 680 685 Thr Ser Ala Asn Cys Ser His Gln Val Lys Gln Gln Ile Ala Thr Thr 690 695 700 Phe Ala Arg Leu Cys Gln Gln Val Asp Ile Thr His Lys Gln Leu Glu 705 710 715 720 Glu Glu Ile Ala Arg Leu Pro Lys Glu Ile Asp Gln Leu Glu Lys Ile 725 730 735 Gln Asn Asn Ser Lys Leu Leu Arg Asn Lys Ala Val Gln Leu Glu Asn 740 745 750 Glu Leu Glu Asn Phe Thr Lys Gln Phe Leu Pro Ser Ser Asn Glu Glu 755 760 765 Ser 

1. An isolated and purified human mitochondrial protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:
 4. 2. A polynucleotide encoding the protein of claim
 1. 3. The polynucleotide of claim 2, which comprises the base sequence for the protein translation region in SEQ ID NO: 1 or SEQ ID NO:
 3. 4. A polynucleotide with which a polynucleotide having the sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or a part thereof hybridizes under a stringent condition.
 5. An expression vector, which expresses the polynucleotide of claim 3 in the in vitro translating system or in a host cell.
 6. A transformant with the expression vector of claim 5, which produces the human mitochondrial protein of claim
 1. 7. An antibody against the human mitochondrial protein of claim
 1. 8. A proteoliposome composed of the human mitochondrial protein of claim 1 and lipid. 